IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Cempra, Inc. And Advises Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Cempra, Inc. ("Cempra" or the "Company") (Nasdaq: CEMP) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.

The investigation focuses on the November 2, 2016 announcement by the U.S. Food and Drug Administration, which posted a preliminary review on its website of Cempra's drug, solithromycin, highlighting a significant safety signal for hepatotoxicity. When this information was announced to the public, shares of Cempra dropped in value.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161103006116/en/
Copyright Business Wire 2010

If you liked this article you might like

Axovant Rises After Tuesday's Plunge - Biotech Movers

Axovant Rises After Tuesday's Plunge - Biotech Movers

These Two Biotech Stocks Are Going Berserk on Wednesday
Biotech Premarket Movers: Cempra, Tesaro, Editas

Biotech Premarket Movers: Cempra, Tesaro, Editas

Biotech Premarket Movers: Cempra, Blueprint Medicines, Aralez

Biotech Premarket Movers: Cempra, Blueprint Medicines, Aralez

Biotech Premarket Movers: Cempra, Novavax, Ionis

Biotech Premarket Movers: Cempra, Novavax, Ionis